Orasis Pharmaceuticals Strengthens Leadership Team with Key Hires to Support the Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%

https://mma.prnewswire.com/media/2528932/Orasis_Jeff_Francis.jpg https://mma.prnewswire.com/media/2528933/Orasis_Sam_Fakhoury.jpg https://mma.prnewswire.com/media/1782272/Orasis_Pharmaceuticals.jpg Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced the appointments of Jeff Francis as Vice President of Sales and Sam Fakhoury as Vice President of Quality and Operations to Orasis’ executive leadership team. Their combined expertise and leadership will support critical functions in the organization to […]

RTX’s Raytheon demos KuRFS and Coyote performance against complex UAS threats

U.S. Army tests prove LIDS effectiveness against enemy drones Raytheon, an RTX (NYSE: RTX) business demonstrated the capabilities of the Ku-band Radio Frequency Sensor, known as KuRFS, the Coyote™Block 2 kinetic effector, and the Block 3 non-kinetic effector during the U.S. Army’s annual summer test period. Testing requirements against high-speed, maneuvering targets, the systems tested

Ribbon’s JITC and FIPS-Compliant Solutions Enable DISA Voice Modernization Mandate

Seamless transition delivers increased security and capabilities Ribbon Communications Inc. (Nasdaq: RBBN), a global provider of real time communications technology and IP optical networking solutions to many of the world’s largest service providers, enterprises, and critical infrastructure operators to modernize and protect their networks, today announced that it has been selected as the technology provider

Halia Therapeutics to Participate in Panel at BIO Investor Forum 2024

— Dr. David J. Bearss, CEO, will partake in a panel focused on Neurodegenerative Disease Targets and Pipelines on Tuesday, October 15 at 11:00-11:50 am PT Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced that David J. Bearss, Ph.D., President and

Options Medical Weight Loss Hosts Grand Opening Party at new St. Charles, Ill. Location–All Are Welcome!

St. Charles Chamber of Commerce and Mayor Lora A. Vitek to join premier medical weight loss clinic for grand opening celebration, October 16 Options Medical Weight Loss, the nation’s premier medical weight loss clinic, is excited to announce the grand opening of a new state-of-the-art clinic in St. Charles, Illinois! To commemorate this milestone, Options

Trulieve Cannabis Corp. to Hold Third Quarter 2024 Results Conference Call on November 5, 2024

Trulieve Cannabis Corp.(CSE: TRUL) (OTCQX: TCNNF)(“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., will hold a conference call on Tuesday, November 5, 2024 at 8:30 AM Eastern Time following the release of its third quarter 2024 financial results. https://mma.prnewswire.com/media/1720011/Trulieve_Logo.jpg Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial

Le-Vel Donates $225,000 in Vital Nutrition, Delivering 64,000 Meals to Aid Hurricane Relief

Global wellness brand donates shakes to aid disaster recovery, supporting hurricane victims with vital nutritional resources Le-Vel, the world leader in premium nutrition and lifestyle products, has generously donated approximately 64,000 of its meal replacement shakes-valued at nearly $225,000-to Convoy of Hope to support those affected by the devastating aftermath of Hurricanes Helene and Milton.

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre’s Portfolio of Potentially Best-in-Class Antibodies and Combinations

SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating robust preclinical activity including comparable potency and a greater than three-fold extension in half-life in NHPs relative to risankizumab1. Spyre portfolio now uniquely includes extended half-life molecules targeting a4B7, TL1A,

TOYO Co., Ltd Announces Plans for a 2 GW Solar Cell Manufacturing Facility in Ethiopia

TOYO Co., Ltd (Nasdaq: TOYO) (“TOYO” or the “Company”),a solar solution company, is excited to announce its plan to establish a state-of-the-art solar cell manufacturing facility with an expected annual capacity of 2 gigawatts (GW). The Company has signed a lease agreement for the new facility that is strategically located in Hawassa, Ethiopia, taking advantage

World Standards Day: Trinasolar leads in standardization and unites efforts to tackle climate challenges

“Standards for the Changing Climate” is the theme of the 55th World Standards Day, set for October 14, 2024.Trinasolar, with its long-standing commitment to tackle climate challenges, recognizes adhering to globally consistent standards is key to ensuring a successful energy transition. As a strong advocate and practitioner of standardization, Trinasolar is dedicated to driving humanity

Scroll to Top